Valuation : Unicycive Therapeutics, Inc.

Market Cap 148M 127M 120M 109M 204M 14.14B 206M 1.43B 550M 7.17B 555M 543M 22.78B P/E 2026 *
-4.39x
P/E 2027 * 3.29x
Enterprise Value 148M 127M 120M 109M 204M 14.14B 206M 1.43B 550M 7.17B 555M 543M 22.78B EV / Sales 2026 *
537x
EV / Sales 2027 * 1.02x
Free-Float
97.74%
Yield 2026 *
-
Yield 2027 * 39.2%
1 day+3.71%
1 week+0.19%
Current month+2.12%
1 month+5.78%
3 months-30.95%
6 months-23.60%
Current year-7.97%
1 week 5.01
Extreme 5.01
5.62
1 month 5.01
Extreme 5.01
5.85
Current year 3.93
Extreme 3.93
8.74
1 year 3.71
Extreme 3.71
8.74
3 years 2.02
Extreme 2.02
18.18
5 years 2.02
Extreme 2.02
31.3
10 years 2.02
Extreme 2.02
87.3
Manager TitleAgeSince
Chief Executive Officer 53 17/08/2016
Director of Finance/CFO 64 28/02/2021
Chief Tech/Sci/R&D Officer - 31/12/2021
Director TitleAgeSince
Chairman 53 17/08/2016
Director/Board Member 58 31/12/2017
Director/Board Member 58 05/09/2023
Date Insider Type Main position Quantity % Market Cap. Importance
14/05/26 Free

Chief Operating Officer

169,500 0.6716%
14/05/26 Free

Executive/Senior Manager

169,500 0.6716%
14/05/26 Free

Chief Financial Officer

169,500 0.6716%
Change 5-day change 1-year change 3-year change Capi.($)
+3.71%+0.19%+23.78%-28.43% 148M
-0.25%-1.36%+44.08%+102.76% 68.24B
+0.54%-3.67%+31.46%+75.07% 62.23B
-1.18%+0.47%-12.78%+384.69% 27.8B
-1.05%-4.43%+30.56%+10.07% 24.86B
-1.76%-6.30%-4.55%-19.75% 24.22B
0.00%-3.65%+14.52%-19.52% 19.36B
-1.86%-2.22%+202.03%+353.89% 17.28B
-1.94%-4.94%-5.29%+495.65% 14.46B
-1.54%-2.88%+52.33%+159.75% 14.23B
Average -0.53%-2.95%+37.61%+151.42% 27.28B
Weighted average by Cap. -0.60%-3.10%+35.57%+136.80%

Financials

2026 *2027 *
Net sales 275K 237K 223K 204K 381K 26.33M 384K 2.66M 1.02M 13.35M 1.03M 1.01M 42.42M 145M 125M 118M 107M 201M 13.9B 203M 1.41B 541M 7.05B 546M 534M 22.4B
Net income -34.12M -29.34M -27.68M -25.22M -47.15M -3.26B -47.57M -330M -127M -1.65B -128M -125M -5.26B 46.27M 39.79M 37.54M 34.2M 63.93M 4.42B 64.51M 447M 172M 2.24B 174M 170M 7.13B
Net Debt - -
Logo Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Employees
22
Date Price Change Volume
10/09/26 US$5.310 +3.71% 1,241,816
09/09/26 US$5.120 +1.79% 906,966
08/09/26 US$5.030 -2.52% 817,178
04/09/26 US$5.160 -2.64% 492,881
03/09/26 US$5.300 +2.12% 836,925
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
5.310USD
Average target price
28.22USD
Spread / Average Target
+431.49%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. UNCY Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!